Bis‐Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile
- 16 May 2018
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 13 (14) , 1414-1420
Abstract
Clostridium difficile infection (CDI) symptoms range from diarrhea to severe toxic megacolon and even death. Due to its rapid acquisition of resistance, C. difficile is listed as an urgent antibiotic‐resistant threat, and has surpassed methicillin‐resistant Staphylococcus aureus (MRSA) as the most common hospital‐acquired infection in the USA. To combat this pathogen, a new structural class of pseudo‐peptides that exhibit antimicrobial activities could play an important role. Herein we report a set of bis‐cyclic guanidine compounds that show potent antibacterial activity against C. difficile with decent selectivity. Eight compounds showed high in vitro potency against C. difficile UK6 with MIC values of 1.0 μg mL−1, and cytotoxic selectivity index (SI) values up to 37. Moreover, the most selective compound is also effective in the treatment of C. difficile‐induced disease in a mouse model of CDI, and appears to be a very promising new candidate for the treatment of CDI.Keywords
Funding Information
- National Science Foundation (CAREER 1351265)
- National Institutes of Health (1R01GM112652-01A1, K01-DK092352, R21-AI113470, R03-DK112004, R01-AI132711)
This publication has 26 references indexed in Scilit:
- Synthesis and Activity of Biomimetic Biofilm DisruptorsJournal of the American Chemical Society, 2013
- Future novel therapeutic agents forClostridium difficileinfectionExpert Opinion on Investigational Drugs, 2010
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)Infection Control & Hospital Epidemiology, 2010
- Cationic compounds with activity against multidrug-resistant bacteria: interest of a new compound compared with two older antiseptics, hexamidine and chlorhexidineClinical Microbiology and Infection, 2010
- In Vitro Activity of Tomopenem (CS-023/RO4908463) against Anaerobic BacteriaAntimicrobial Agents and Chemotherapy, 2009
- Update on the changing epidemiology of Clostridium difficile-associated diseaseNature Clinical Practice Gastroenterology & Hepatology, 2008
- Increase in Clostridium difficile –related Mortality Rates, United States, 1999 – 2004Emerging Infectious Diseases, 2007
- A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and MortalityNew England Journal of Medicine, 2005
- Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, CanadaClinical Infectious Diseases, 2005
- Antibiotic-Associated DiarrheaNew England Journal of Medicine, 2002